The Trump administration’s fiscal year 2026 budget request proposed collapsing the National Institutes of Health’s 27 Institutes and Centers (ICs) into eight. Congress rejected that plan when it finalized FY2026 appropriations in February 2026, and NIH’s 27-IC structure remains intact today. That is not the end of the story, though: sector reporting through mid-2026 describes NIH pursuing pieces of the same restructuring administratively, without a change in law. This piece separates what was proposed, what Congress actually did, and what is credibly reported to be happening now, so research offices can track the difference between a legislative fact and an administrative trend.
What the original 27-to-8 plan proposed
NIH’s FY2026 budget justification, released alongside the broader HHS FY2026 request in 2025, proposed reorganizing the agency’s 27 Institutes and Centers into eight entities and cutting the agency’s topline budget by roughly 40%, from the high-$40-billion range to a proposed $27.9 billion. Under the plan as reported, only three ICs would have survived as standalone institutes: the National Cancer Institute (NCI), the National Institute of Allergy and Infectious Diseases (NIAID), and the National Institute on Aging (NIA). The remaining ICs would have been folded into five newly created umbrella institutes — for example, a proposed National Institute of Behavioral Health that would have combined the National Institute on Alcohol Abuse and Alcoholism (NIAAA), the National Institute on Drug Abuse (NIDA), and the National Institute of Mental Health (NIMH) into a single entity (Science/AAAS; Hooper, Lundy & Bookman).
The administration framed this as administrative streamlining, but it is worth understanding why the proposal needed Congress at all: most of NIH’s Institutes and Centers exist in statute, several by name in the NIH Reform Act of 2006 (42 U.S.C. §281 et seq.) and earlier organic acts for individual institutes such as the National Cancer Act. Eliminating or merging a statutorily named institute — as opposed to reorganizing offices within one — generally requires authorizing legislation, not just a budget request or an appropriations rider. That legal reality shaped both how the plan was pursued and how it was blocked.
Where it stands: Congress rejected the consolidation in the FY2026 spending bill
Congress did not adopt the 27-to-8 restructuring. On February 3, 2026, Congress passed and the President signed the FY2026 spending legislation funding NIH at $48.7 billion — roughly flat with FY2025 — while leaving the existing 27-institute structure in place. Appropriators from both chambers described the outcome as a rebuke of the administration’s proposed downsizing rather than a partial compromise (see CASRAI’s companion piece, NIH funding cuts in 2026: what actually happened, for the full appropriations and litigation timeline). The Congressional Research Service’s ongoing report on NIH funding history, CRS Report R43341, “National Institutes of Health (NIH) Funding: FY1996-FY2026” — most recently updated in May 2026 — tracks this outcome alongside the longer funding history and is the most current primary reference for exact appropriations figures as they’re finalized.
In short: as a matter of law and appropriated funding, NIH still has 27 Institutes and Centers as of this writing, not eight. Any claim that the consolidation has been formally enacted is not accurate.
What’s reportedly happening administratively anyway
Congress blocking the statutory restructuring does not fully settle the question, because an administration retains considerable authority over how it runs an agency internally — which office reviews what, how funding announcements get issued, which web presence a program uses — short of eliminating a statutorily named institute outright. Research-policy newsletters and sector trackers have reported a series of smaller administrative changes through the first half of 2026 that move NIH’s operations in the direction the rejected plan would have taken it, even though the formal IC structure has not changed:
- Centralizing funding-opportunity approval. Reporting describes individual institutes and centers losing standing authority to issue their own specialized Funding Opportunity Announcements (FOAs) without central Office of the Director sign-off, with a stated aim of reducing the overall number of IC-specific FOAs.
- Consolidating public-facing IC websites into a more centralized NIH web presence rather than the traditionally separate site each institute maintained.
- Steering applicants toward centralized discovery tools — for example, a centralized “Explore NIH Opportunities” search tool and Grants.gov — rather than browsing funding opportunities institute-by-institute.
- Aligning application receipt dates across areas that previously ran on institute-specific schedules (HIV/AIDS-related applications are one documented example) with NIH’s standard due dates.
Treat this list as directionally reported by sector trackers rather than confirmed against a single official NIH policy document enumerating “the reorganization” — NIH has not published a consolidated announcement declaring the 27-to-8 plan in effect, because it isn’t. What’s verifiable is narrower and more incremental: individual notices and operational changes that, taken together, centralize functions that used to sit at the institute level. Research offices should treat each change (an FOA process shift, a due-date alignment, a site consolidation) as its own discrete, checkable fact — via the NIH Guide for Grants and Contracts and individual IC notices — rather than assuming a single master reorganization order governs all of it.
Why this matters for research administration offices
- The formal structure hasn’t changed. Grant mechanisms, study section assignments, and IC-specific policies (e.g., an institute’s payline or funding strategy) are still organized around the existing 27 ICs. Don’t restructure internal tracking or IC-relationship management around the proposed 8-institute map — it isn’t the operative structure.
- Central review of FOAs can mean slower or fewer specialized calls. If your institution relies on a specific IC’s narrow funding mechanism, watch for that IC’s FOA cadence changing even though the IC itself hasn’t been eliminated.
- Don’t conflate this with the separate funding-cuts and indirect-cost stories. The 27-to-8 structural proposal, the FY2026 appropriations fight, NIH’s indirect-cost rate actions, and individual grant terminations are related but legally and procedurally distinct developments — see NIH funding cuts in 2026: what actually happened for the budget and litigation specifics, and NIH’s Proposed 15% Indirect Cost Cap for that separate policy thread.
- Track primary sources, not the original proposal. Because the 27-to-8 plan was never enacted, older 2025 coverage describing “NIH’s new eight institutes” as settled fact is out of date. Check current NIH Guide Notices and the CRS report above for what’s actually in force.
Frequently asked questions
Has NIH actually been reorganized into 8 institutes?
No. The FY2026 spending law Congress passed and the President signed on February 3, 2026 preserved NIH’s existing 27 Institutes and Centers. The 8-institute structure was a budget proposal, not an enacted reorganization.
Which NIH institutes would have been eliminated under the original proposal?
As reported, only the National Cancer Institute, the National Institute of Allergy and Infectious Diseases, and the National Institute on Aging would have remained standalone institutes under the rejected plan; the other 24 ICs would have been consolidated into five new umbrella institutes.
Could the consolidation still happen later?
A wholesale merger of statutorily established institutes would generally require new authorizing legislation from Congress, not just a future appropriations bill or an administration decision. Short of that, NIH retains latitude to make administrative-level changes (funding-announcement review, web presence, application scheduling) that move operations in a similar direction without changing the legal IC structure — which is the pattern sector reporting describes as of mid-2026.
Does this affect how I should track NIH funding opportunities right now?
Institute-specific FOAs may be reviewed centrally before release and, per reporting, may become less frequent — so research offices that rely on a narrow, institute-specific mechanism should monitor that IC’s notices directly rather than assuming past FOA cadence will continue unchanged.
